Related Experiment Video
Updated: Oct 16, 2025
07:15
Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
Published on: July 3, 2025
326
Soluble Guanylate Cyclase Stimulators in Heart Failure
Sajog Kansakar1, Ashish Guragain2, Deepak Verma3
1Internal Medicine, Manipal College of Medical Sciences, Pokhara, NPL.
Cureus
|October 18, 2021
Summary
Soluble guanylate cyclase stimulators significantly reduce hospitalizations in high-risk heart failure patients with reduced ejection fraction. These novel agents show no benefit for heart failure with preserved ejection fraction.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Science
Background:
- Heart failure presents a substantial global health challenge with high morbidity and mortality rates.
- Despite medical advancements, heart failure prognosis remains poor, necessitating novel therapeutic strategies.
- Soluble guanylate cyclase (sGC) stimulators have emerged as promising agents in recent clinical trials.
Purpose of the Study:
- To elucidate the guanylate cyclase signaling pathway.
- To define the role of sGC stimulators in managing heart failure.
- To review recent clinical trial data on sGC stimulators for heart failure.
Main Methods:
- Literature review of the guanylate cyclase signaling pathway.
- Analysis of clinical trial data for sGC stimulators in heart failure.
- Synthesis of evidence regarding efficacy in different heart failure subtypes.
Main Results:
- sGC stimulators demonstrated significant reductions in hospitalizations for heart failure with reduced ejection fraction (HFrEF) in high-risk populations.
- These benefits were observed specifically in patients with HFrEF who were at high risk for cardiovascular events.
- No significant benefits were identified for patients with heart failure with preserved ejection fraction (HFpEF).
Conclusions:
- sGC stimulators offer significant therapeutic advantages for reducing hospitalizations in high-risk HFrEF patients.
- Current evidence does not support the use of sGC stimulators in patients with HFpEF.
- Further research may explore mechanisms for HFpEF or alternative therapeutic targets.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
830
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
830
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
572
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
572
01:30Heart Failure V: Medical Management
51
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
51
01:22Heart Failure Drugs: β-Blockers
485
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
485
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.2K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.2K
01:22Heart Failure Drugs: Diuretics
531
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
531